SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology shares faced a significant sell-off following quarterly results, as investors expressed concern over compressed gross margins and the pace of future growth despite the company reporting an earnings beat and providing raised revenue guidance. While the drop sparked intense debate and volatility, many traders viewed the sharp decline as an overreaction and a potential buying opportunity, citing strong long-term fundamentals and the company's role in the AI connectivity market.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

The community is focused on the anticipation of a positive ALJ recommendation and subsequent DEA final ruling to move cannabis to Schedule III, viewing this as a critical catalyst for industry-wide tax relief and institutional adoption. While some traders express frustration with price suppression and algorithmic trading, others maintain a bullish long-term outlook, emphasizing that the current price remains undervalued relative to expected regulatory developments.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is seeing high market interest driven by its strong fiscal fourth-quarter results, beating Wall Street expectations for both earnings and revenue. While the stock initially retreated following the report, traders remain divided over the company's valuation and the role of acquisition-fueled versus organic revenue growth, even as analysts continue to issue bullish price target updates.

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy shares are experiencing volatility following a third-quarter earnings report that missed revenue and earnings expectations, primarily due to rising costs from data center project scaling and module delivery delays. Despite the financial miss and concerns regarding ongoing dilution, retail sentiment remains sharply divided as some traders emphasize long-term growth potential from the company's data center power pipeline and backlog.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Investors are largely dismissive of a recent Federal Circuit ruling invalidating several older patents, viewing it as a "nothing burger" because these assets were already considered lost at the PTAB level and are not part of the active, high-value litigation against Micron. Sentiment remains bullish as the community focuses on the upcoming September 9 oral arguments regarding the more critical 912 and 417 patents and the pending $445 million judgment.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is trending after reporting strong quarterly results that exceeded expectations and raising its full-year outlook, driven by surging demand for AI-optimized servers. While retail sentiment remains optimistic regarding the company's long-term growth potential and record AI order backlog, traders are expressing frustration over intraday volatility and significant price swings, leading to debate over whether the stock is being manipulated or if investors are simply locking in profits.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is trending as investors and traders closely monitor the stock ahead of its upcoming quarterly earnings report. While some traders are expressing bearish sentiment due to valuation concerns and insider selling, others remain bullish on the company's enterprise AI and data-cloud growth potential, highlighting recent analyst price target increases as a sign of continued institutional demand.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPath Technologies is trending following a recent price pullback that community members attribute to broader sector volatility, momentum trading, and speculation regarding potential delays in the Next Generation Short Range Interceptor (NGSRI) program. While some traders express concern over the downward price action, others view the current levels as a buying opportunity based on the company's long-term backlog and critical role in the defense supply chain.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending as investors monitor anticipation for upcoming earnings, with sentiment divided between expectations of a strong AI-driven growth catalyst and concerns over volatility and management's past performance. Traders are actively debating whether current price levels offer a buying opportunity ahead of potential upside momentum.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

A large equity offering is driving the selloff and debate, with traders focused on dilution, the discounted pricing, and concerns that management weakened momentum. Bulls argue the raise provides permanent capital to expand capacity for strong AI-infrastructure and hyperscaler demand, while skeptics question the timing and near-term shareholder impact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its officers and directors for alleged breaches of fiduciary duty. Shareholders who have held REGENXBIO shares continuously since prior to February...

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli PR Newswire ROCKVILLE, Md., Aug. 25, 2026 ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc.(Nasdaq: RGNX) today announced the appointment...

Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street

Equity

Clear Street said the FDA decision would significantly delay Regenxbio’s resubmission of its application and a potential voucher that could bring in additional cash.


RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ‘Disappointing’ FDA Hold On Gene Therapy

BofA called the clinical hold on RGX-121 disappointing and a reversal of July’s progress but kept a $15 price target on the stock. 


Why Did RGNX Stock Crash Today?

Regenxbio said the FDA has placed a clinical hold on its Hunter syndrome therapy after the discovery of unusual spine MRI findings in five participants in a study.


Futures Slide Ahead Of "Pivotal Week" With Nvidia Earnings. Warsh Speech On Deck

Futures Slide Ahead Of "Pivotal Week" With Nvidia Earnings. Warsh Speech On Deck

 Futures are lower with Tech underperforming as the market focuses on NVDA / MRVL earnings this week; while the AI theme is pressured globally and memory stocks slump driven by a slide in the Kospi. Futures...

Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold

Regenxbio stock drops over 23% following an FDA clinical hold on its Hunter Syndrome gene therapy RGX-121 due to spine MRI findings.read more...

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II REGENXBIO Announces Regulatory Update on RGX-121 for MPS II PR Newswire ROCKVILLE, Md., Aug. 24, 2026 ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy...

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of $0.43 up 131.16% YoY
• Reported revenue of $108.02M up 405.73% YoY
• REGENXBIO expects its balance in cash, cash equivalents, and marketable securities as of June 30, 2026, plus July 2026 proceeds, are sufficient to fund operations for REGENXBIO into Q4 2027.

REGENXBIO faces structural revenue headwinds from expired ZOLGENSMA patents, a significant reduction in cash reserves during the first half of 2026, and increased general and administrative expenses for REGENXBIO.

REGENXBIO achieved positive clinical trial results for RGX-202, secured a $100 million milestone payment from AbbVie, and received favorable regulatory feedback from the FDA regarding the RGX-121 BLA resubmission.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Current Price	$9.37
Prev Close	$9.32
Open	$9.50
Dividend Yield	0.00%
50-Day Moving Average	$11.00
Beta	1.70
Avg. Volume	1.34M
PE Ratio	-2.46

52-Week High	$16.19
52-Week Low	$5.46
Market Capitalization	$615.24M
EPS (Annual)	-$3.76
Price to Book	7.03
Revenue Per Employee	$459,409.70

Feed

News

Sentiment

Earnings

Fundamentals

Info